busulfan has been researched along with Sensitivity and Specificity in 22 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Busulfan is an alkylating agent used to ablate bone marrow cells before hematopoietic stem cell transplantation." | 1.42 | High-Throughput Validated Method for the Quantitation of Busulfan in Plasma Using Ultrafast SPE-MS/MS. ( Danso, D; Enger, R; Jannetto, PJ; Langman, LJ, 2015) |
| " To solve this problem, we proposed a new dosing scheme, in which the amount of dose was adjusted dynamically according to the estimated precision of the AUC estimator." | 1.39 | A proposed dynamic dosing scheme to secure the target plasma drug concentrations based on the precision of the AUC estimate. ( Tsuruta, H; Wada, T, 2013) |
| " Intra- and inter-day precision and accuracy of the measurement fulfilled analytical criteria accepted in pharmacokinetic studies." | 1.34 | Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. ( Grund, G; Główka, FK; Wachowiak, J; Łada, MK, 2007) |
| "5 min), and the whole procedure can be completed in 4-5 h, which would permit dose corrections after the third dose allowing earlier and better dosing adjustments towards the target level of busulfan." | 1.33 | Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. ( Azevedo, Dde A; dos Reis, EO; Lima, EL; Suarez-Kurtz, G; Vianna-Jorge, R, 2005) |
| " This method was used to determine the pharmacokinetic parameters of busulfan after the first administration of 1 mg/kg orally, in 13 children receiving the drug as part of the preparative regimen for bone marrow transplantation." | 1.31 | Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children. ( Aigrain, EJ; Duval, M; Litalien, C; Quernin, MH; Vilmer, E, 2001) |
| "The development and validation of a high-performance liquid chromatographic (HPLC) assay for determination of busulfan concentrations in human plasma for pharmacokinetic studies is described." | 1.30 | Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan. ( Barnett, MJ; Burns, RB; Embree, L; Fung, HC; Heggie, JR; Knight, G; Ng, CS; Spinelli, JJ; Wu, M, 1997) |
| "Busulfan (BU) is a widely used alkylating agent for antineoplastic therapy and marrow ablation in preparation for bone marrow transplantation (BMT)." | 1.30 | Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. ( Lai, WK; Law, LK; Li, CK; Pang, CP; Wong, R; Yuen, PM, 1998) |
| "Busulfan was extracted in toluene, derivatized by 2,3,5,6-tetrafluorothiophenol to obtain di-TFTP-butane, the derivatization product was then re-extracted in toluene and injected into the HPLC system with ultraviolet detection (wavelength: 275 nm)." | 1.30 | High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. ( Chandy, M; Dennison, D; Jacqz-Aigrain, E; Krishnamoorthy, R; Médard, Y; Poonkuzhali, B; Quernin, MH; Srivastava, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (50.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, A | 1 |
| Winter, G | 1 |
| Tan, S | 1 |
| Saco, A | 1 |
| Alòs, S | 1 |
| Esteve, R | 1 |
| Suárez-Lledó, M | 1 |
| Martínez, C | 1 |
| Perez, FM | 1 |
| Vega, N | 1 |
| Martí, C | 1 |
| Torne, A | 1 |
| Ordi, J | 1 |
| Del Pino, M | 1 |
| Tsuruta, H | 1 |
| Wada, T | 1 |
| Danso, D | 1 |
| Jannetto, PJ | 1 |
| Enger, R | 1 |
| Langman, LJ | 1 |
| Fernández de Larrea, C | 1 |
| Tovar, N | 1 |
| Rozman, M | 1 |
| Rosiñol, L | 1 |
| Aróstegui, JI | 1 |
| Cibeira, MT | 1 |
| Rovira, M | 1 |
| Yagüe, J | 1 |
| Bladé, J | 1 |
| Skoglund, C | 1 |
| Bassyouni, F | 1 |
| Abdel-Rehim, M | 1 |
| Jenke, A | 1 |
| Renner, U | 1 |
| Schuler, US | 1 |
| Wauer, S | 1 |
| Leopold, T | 1 |
| Schleyer, E | 1 |
| Ehninger, G | 1 |
| dos Reis, EO | 1 |
| Vianna-Jorge, R | 1 |
| Suarez-Kurtz, G | 1 |
| Lima, EL | 1 |
| Azevedo, Dde A | 1 |
| Główka, FK | 1 |
| Łada, MK | 1 |
| Grund, G | 1 |
| Wachowiak, J | 1 |
| Embree, L | 2 |
| Burns, RB | 2 |
| Heggie, JR | 2 |
| Phillips, GL | 1 |
| Reece, DE | 1 |
| Spinelli, JJ | 2 |
| Hartley, DO | 1 |
| Hudon, NJ | 1 |
| Goldie, JH | 1 |
| Wu, M | 1 |
| Ng, CS | 1 |
| Fung, HC | 1 |
| Knight, G | 1 |
| Barnett, MJ | 1 |
| Lassau, N | 1 |
| Leclère, J | 1 |
| Auperin, A | 1 |
| Bourhis, JH | 1 |
| Hartmann, O | 1 |
| Valteau-Couanet, D | 1 |
| Benhamou, E | 1 |
| Bosq, J | 1 |
| Ibrahim, A | 1 |
| Girinski, T | 1 |
| Pico, JL | 1 |
| Roche, A | 1 |
| Chow, DS | 1 |
| Bhagwatwar, HP | 1 |
| Phadungpojna, S | 1 |
| Andersson, BS | 1 |
| Quernin, MH | 3 |
| Poonkuzhali, B | 2 |
| Montes, C | 1 |
| Krishnamoorthy, R | 2 |
| Dennison, D | 2 |
| Srivastava, A | 2 |
| Vilmer, E | 2 |
| Chandy, M | 2 |
| Jacqz-Aigrain, E | 2 |
| Anguita, E | 1 |
| Villegas, A | 1 |
| Díaz-Mediavilla, J | 1 |
| González, FA | 1 |
| del Potro, E | 1 |
| Espinós, D | 1 |
| Lai, WK | 1 |
| Pang, CP | 1 |
| Law, LK | 1 |
| Wong, R | 1 |
| Li, CK | 1 |
| Yuen, PM | 1 |
| Médard, Y | 1 |
| Ritter, CA | 1 |
| Bohnenstengel, F | 1 |
| Hofmann, U | 1 |
| Kroemer, HK | 1 |
| Sperker, B | 1 |
| Peris, JE | 1 |
| Latorre, JA | 1 |
| Castel, V | 1 |
| Verdeguer, A | 1 |
| Esteve, S | 1 |
| Torres-Molina, F | 1 |
| Dow, AD | 1 |
| Finlay, G | 1 |
| Bloomfield, MS | 1 |
| Bleyzac, N | 1 |
| Barou, P | 1 |
| Aulagner, G | 1 |
| Duval, M | 1 |
| Litalien, C | 1 |
| Aigrain, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients[NCT03963999] | Phase 4 | 0 participants (Actual) | Interventional | 2020-04-01 | Withdrawn (stopped due to We did not receive grant funding. We will reapply in June of 2020) | ||
| Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study[NCT03426358] | 1,101 participants (Actual) | Interventional | 2015-04-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for busulfan and Sensitivity and Specificity
| Article | Year |
|---|---|
Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection?
Topics: Adult; Biomarkers, Tumor; Blotting, Southern; Busulfan; Female; Fusion Proteins, bcr-abl; Humans; Le | 1998 |
1 trial available for busulfan and Sensitivity and Specificity
| Article | Year |
|---|---|
Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; B | 2011 |
20 other studies available for busulfan and Sensitivity and Specificity
| Article | Year |
|---|---|
Stability-Indicating Method Development and Validation for Busulfan Drug Substance by Gas Chromatography-Flame Ionization Detector.
Topics: Busulfan; Butylene Glycols; Chromatography, Gas; Drug Contamination; Drug Stability; Flame Ionizatio | 2021 |
Atypical cytological changes mimicking SIL of the uterine cervix in allogenic hematopoietic stem cell transplantation recipients treated with busulfan.
Topics: Adult; Busulfan; Cervix Uteri; Colposcopy; Diagnostic Errors; False Positive Reactions; Female; Foll | 2019 |
A proposed dynamic dosing scheme to secure the target plasma drug concentrations based on the precision of the AUC estimate.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Computer Simulation; Drug Therapy, Computer-Assisted; H | 2013 |
High-Throughput Validated Method for the Quantitation of Busulfan in Plasma Using Ultrafast SPE-MS/MS.
Topics: Alkylating Agents; Busulfan; Drug Monitoring; Drug Stability; Gas Chromatography-Mass Spectrometry; | 2015 |
Monolithic packed 96-tips set for high-throughput sample preparation: determination of cyclophosphamide and busulfan in whole blood samples by monolithic packed 96-tips and LC-MS.
Topics: Busulfan; Chromatography, Liquid; Cyclophosphamide; High-Throughput Screening Assays; Humans; Methac | 2013 |
Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis.
Topics: Busulfan; Chromatography, High Pressure Liquid; Photolysis; Reference Standards; Reproducibility of | 2004 |
Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Alkylating Agents; Busulfan; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Reproduc | 2005 |
Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Chromatography, Hi | 2007 |
Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.
Topics: Busulfan; Calibration; Chromatography, Gas; Drug Monitoring; Humans; Phenols; Reference Standards; R | 1993 |
Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan.
Topics: Busulfan; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Reference Standards; Repr | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples.
Topics: Animals; Antineoplastic Agents, Alkylating; Busulfan; Chromatography, High Pressure Liquid; Dogs; Dr | 1997 |
Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol.
Topics: Alkylating Agents; Busulfan; Child; Child, Preschool; Gas Chromatography-Mass Spectrometry; Humans; | 1998 |
Routine analysis of plasma busulfan by gas chromatography-mass fragmentography.
Topics: Adolescent; Alkylating Agents; Busulfan; Child; Gas Chromatography-Mass Spectrometry; Humans; Sensit | 1998 |
High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Child; Chromatography, High Pressure Liquid; Gas Chroma | 1999 |
Determination of tetrahydrothiophene formation as a probe of in vitro busulfan metabolism by human glutathione S-transferase A1-1: use of a highly sensitive gas chromatographic-mass spectrometric method.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Busulfan; Calibration; Gas Chromatography-Mass Spectr | 1999 |
Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Calibration; Chromatography, High Pressure Liquid; Huma | 1999 |
The determination of busulphan in dissolution samples by flow injection analysis.
Topics: Busulfan; Colorimetry; Evaluation Studies as Topic; Flow Injection Analysis; Pyridines; Reproducibil | 1999 |
Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Calibration; Chromatography, High Pressure Liquid; Huma | 2000 |
Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Chromato | 2001 |